Efficacy and tolerability of amlodipine/valsartan combination therapy in hypertensive patients not adequately controlled on valsartan monotherapy

Current Medical Research and Opinion

Volumn 25, Issue 2, 2009, Pages 315-324

  Sinkiewicz, Wladyslaw ^a   Glazer, R D ^b   Kavoliuniene, A ^c   Miglinas, M ^d   Prak, H ^e   Wernsing, M ^b   Yen, J ^b  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b NOVARTIS PHARMA AG   (Switzerland)

^c KAUNAS UNIVERSITY OF MEDICINE HOSPITAL   (Lithuania)

^d VILNIUS UNIVERSITY   (Lithuania)

^e NONE   (Netherlands)

Author keywords

Amlodipine; Angiotensin II receptor blockers; Calcium channel blockers; Combination therapy; Valsartan

Indexed keywords

AMLODIPINE PLUS VALSARTAN; VALSARTAN; AMLODIPINE; ANTIHYPERTENSIVE AGENT; DRUG DERIVATIVE; TETRAZOLE DERIVATIVE; VALINE;

ABDOMINAL PAIN; ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BACKACHE; BLOOD PRESSURE REGULATION; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; FATIGUE; FEMALE; FLUSHING; HEART INFARCTION; HUMAN; INFLUENZA; JOINT SWELLING; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; ORTHOSTATIC HYPOTENSION; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE BLIND PROCEDURE; SITTING; SYSTOLIC BLOOD PRESSURE; THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION; DRUG COMBINATION; HYPERTENSION; MIDDLE AGED;

AMLODIPINE; ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; SINGLE-BLIND METHOD; TETRAZOLES; VALINE;

EID: 64249096233     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990802630588     Document Type: Article

References (33)

1. Hajjar I, Kotchen TA. Trends in the prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003;290:199-206
2. Fields LE, Burr VL, Cutler JA, et al. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension 2004;44:398-404
3. Chobanian AV, Bakris GL, Black HR, et al., for the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, the National Heart, Lung, and Blood Institute, and the National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-1252
4. Neutel JM, Smith DH, Weber MA. Low-dose combination therapy: an important first-line treatment in the management of hypertension. Am J Hypertens 2001;14:286-292 (Pubitemid 32202714)
5. Kulkarni SP, Alexander KP, Lyde B, et al. Long-term adherence with cardiovascular drug regimens. Am Heart J 2006;151:185-191 (Pubitemid 41815352)
6. Lewington S, Clarke R, Qizilbash N, et al., for the Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies [published correction appears in Lancet 2003;361:1060]. Lancet 2002;360:1903-13
7. Mancia G, de Backer G, Dominiczak A, et al. Guidelines for the Management of Arterial Hypertension - The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-1187 (Pubitemid 46924065)
8. Cifkova R, Erdine S, Fagard R, et al., for the ESH/ESC Hypertension Guidelines Committee. Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens 2003;21:1779-1786 (Pubitemid 37290093)
9. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002;62:443-462 (Pubitemid 34208333)
10. Weber MA. Creating a combination antihypertensive regimen: what does the research show? J Clin Hypertens (Greenwich) 2003;5:12-20
11. Elliott WJ. Is fixed combination therapy appropriate for initial hypertension treatment? Curr Hypertens Rep 2002;4:278-285
12. Jamerson KA, Nwose O, Jean-Louis L, et al. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am J Hypertens 2004;17:495-501 (Pubitemid 38726163)
13. Malacco E, Vari N, Capuano V, et al. A randomised, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study. Clin Ther 2003;25:2765-2780 (Pubitemid 37521249)
14. Basile J. The role of existing and newer calcium channel blockers in the treatment of hypertension. J Clin Hypertens (Greenwich) 2004;6:621-629
15. Oparil S, Dyke S, Harris F, et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther 1996;18:797-810 (Pubitemid 26397279)
16. Black HR, Graff A, Shute D, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J Hum Hypertens 1997;11:483-489 (Pubitemid 27434775)
17. Schmieder RE. Mechanisms for the clinical benefits of angiotensin II receptor blockers. Am J Hypertens 2005;18:720-730 (Pubitemid 40692442)
18. Wong ND, Thakral G, Franklin SS, et al. Preventing heart disease by controlling hypertension: impact of hypertension subtype, stage, age, and sex. Am Heart J 2003;145:888-895 (Pubitemid 36570961)
19. Cheung BMY, Ong KL, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension: United States National Health and Nutrition Examination Survey 2001-2002. J Clin Hypertens (Greenwich) 2006;8:93-98
20. Staessen JA, Li Y, Thijs L, et al. Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Hypertens Res 2005;28:385-407
21. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet 2004;363:2049-2051 (Pubitemid 38781107)
22. Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003;326:1427-1434 (Pubitemid 36776153)
23. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-153 (Pubitemid 30051645)
24. Nissen SE, Tuzcu EM, Libby P, et al., for CAMELOT Investigators. Effects of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004;292:2217-2226
25. Staessen JA, Thijs L, Fagard R, et al. for Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe trial. J Hypertens 2004;22:847-857
26. Kjeldsen SE, Aksnes TA, de la Sierra A, et al. Amlodipine and valsartan: calcium channel blockers/angiotensin II receptor blockers combination for hypertension. Therapy 2007;4:31-40 (Pubitemid 46322247)
27. Dagenais NJ, Jamali F. Protective effects of angiotensin II interruption: evidence for antiinflammatory actions. Pharmacotherapy 2005;25:1213-1229 (Pubitemid 41244813)
28. Zhou MS, Schulman IH, Raij L. Nitric oxide, angiotensin II, and hypertension. Semin Nephrol 2004;24:366-378 (Pubitemid 38900636)
29. Siragy HM, Xue C, Webb RL. Beneficial effects of combined benazepril-amlodipine on cardiac nitric oxide, cGMP, and TNF-α production after cardiac ischemia. J Cardiovasc Pharmacol 2006;47:636-642 (Pubitemid 44309655)
30. Iadecola C, Gorelick PB. Hypertension, angiotensin, and stroke: beyond blood pressure. Stroke 2004;35:348-350 (Pubitemid 38174402)
31. Smith TR, Philipp T, Vaisse B, et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomised, placebo-controlled studies. J Clin Hypertens (Greenwich) 2007;9:355-364
32. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomised, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007;29:563-580 (Pubitemid 47028551)
33. Allemann Y, Fraile B, Lambert M, et al. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: The Exforge in Failure After Single Therapy (EX-FAST) Study. J Clin Hypertens (Greenwich) 2008;10:1-10